B cell lymphomas are cancers that arise from cells that depend on numerous highly
orchestrated interactions with immune and stromal cells in the course of normal …

Over the last decade, the active role of the microenvironment in the pathogenesis of B cell
lymphomas has been recognized, delivering signals that favor clonal expansion and drug …

Targeting the B-cell receptor signaling pathway through BTK inhibition proved to be effective
for the treatment of chronic lymphocytic leukemia (CLL) and other B-cell lymphomas …

Follicular lymphoma (FL) is the most frequent indolent B cell lymphoma and is still
considered to be incurable. In recent years, whole-exome sequencing studies of large …

Follicular lymphoma (FL) results from the accumulation of malignant germinal center (GC) B
cells leading to the development of an indolent and largely incurable disease. FL cells …

The B cell receptor (BCR) pathway has been identified as a potential therapeutic target in a
number of common B cell malignancies, including chronic lymphocytic leukemia, diffuse …

Altered expression of matricellular proteins can become pathogenic in the presence of
persistent perturbations in tissue homeostasis. Here, we show that autoimmunity associated …

Vimentin has been implicated in pulmonary sarcoidosis as a T-cell autoantigen, particularly
in the context of HLA-DRB1* 03, the Vα2. 3/Vβ22 T-cell receptor (TCR), and Löfgren's …

Kinases downstream of B-cell antigen receptor (BCR) represent attractive targets for therapy
in non-Hodgkin lymphoma (NHL). As clinical responses vary, improved knowledge …

The development of follicular lymphoma (FL) from a founder B cell with an upregulation of B-
cell lymphoma 2 (BCL2), via the t (14; 18) translocation, to a proliferating clone, poised to …